Key result
Two doses of inactivated EV71 vaccine maintained a high seropositive rate of neutralizing antibodies at 5 years compared to placebo.
Why the study?
Does a 2-dose inactivated EV71 vaccine provide persistent immunity at 5 years in healthy children?
RCT (n=211)
Randomly administrated
Does a 2-dose inactivated EV71 vaccine provide persistent immunity at 5 years in healthy children?
The inactivated EV71 vaccine provides persistent immunity for at least 5 years following primary vaccination.
Answers are grounded in this paper and cite their sources.
Sustained seropositivity 5 years after two-dose EV71 vaccination supports durable immunity; extends Phase III RCT evidence on persistence.
The longevity of antibodies induced by inactivated enterovirus 71 type (EV71) vaccine is not well studied. To estimate the immunity persistence following two-dose vaccination of EV71 vaccine, a five-year follow-up study was conducted as an extension of a Phase III clinical trial. In this study, a sub-cohort of volunteers who was eligible for enrollment and randomly administrated either 2 dose EV71 vaccine or placebo in the phase III clinical trial was selected, and then further observed 64 months post the 1st vaccination. 211 Subjects (106 vaccine subjects and 105 placebo subjects) who provided a full series of blood samples (at all the sampling points) were included in the final analyzed population. Seropositive rate (SR) and geometric mean titer (GMT) of the neutralizing antibodies (NAb) was calculated to detect the dynamic profiles of EV71 vaccine-induced immunogenicity. SR at the 5th year remained 94.34% in the vaccine subjects, with a GMT of 141.42. The SR was 71.43% in the placebo subjects, with a GMT of 71.83. Despite natural infection consistently promoted the NAb increase in the placebo subjects, the SR and GMT in vaccine subjects remained significantly higher than that in the placebo subjects at all the sampling points. The inactivated EV71 vaccine-induced immunity had a good persistence, within 5 years following the primary vaccination.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2018) conducted an RCT in Healthy children (n=211). Inactivated enterovirus 71 type (EV71) vaccine vs. Placebo was evaluated on Seropositive rate (SR) of neutralizing antibodies at the 5th year. Two doses of inactivated EV71 vaccine maintained a high seropositive rate of neutralizing antibodies at 5 years compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: